Overview

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

Status:
Recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This Phase 1, single centre, open label dose escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-cells (WZTL-002) in the treatment of patients with relapsed or refractory (r/r) B-cell Non Hodgkin Lymphoma, for use in further efficacy trials.

Phase:

Phase 1

Details

Lead Sponsor:

Malaghan Institute of Medical Research

Collaborators:

Wellington Zhaotai Therapies Limited
Wellington Zhaotai Therapies Limited (WZTL)

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate